Patents by Inventor Joaquín Pastor Fernández

Joaquín Pastor Fernández has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240199630
    Abstract: The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine of formula (I): which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so the compounds of the invention are useful for the prevention and/or treatment of cancer, alone or in combination with chemotherapeutic agents.
    Type: Application
    Filed: March 23, 2022
    Publication date: June 20, 2024
    Inventors: Joaquín PASTOR FERNÁNDEZ, Sonia MARTÍNEZ GONZÁLEZ, Carmen BLANCO APARICIO, Ana Belén GARCÍA GARCÍA, Sonsoles RODRÍGUEZ ARÍSTEGUI, Cristina Ana GÓMEZ DE LA OLIVA, María Isabel ALBARRÁN SANTIÑO, Antonio CEBRIÁ GÓMEZ, Marcos MALUMBRES MARTÍNEZ
  • Patent number: 10208056
    Abstract: There is provided compounds of formula I, wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: February 19, 2019
    Assignee: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
    Inventors: Joaquín Pastor Fernández, Sonia Martínez González, Carmen Blanco-Aparicio, Ana Isabel Hernández Higueras, Cristina Ana Gómez De La Oliva, Virginia Rivero Buceta, Rosario Concepción Riesco Fagundo
  • Publication number: 20180244687
    Abstract: There is provided compounds of formula I, wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Inventors: Joaquín PASTOR FERNÁNDEZ, Sonia MARTÍNEZ GONZÁLEZ, Carmen BLANCO-APARICIO, Ana Isabel HERNÁNDEZ HIGUERAS, Cristina Ana GÓMEZ DE LA OLIVA, Virginia RIVERO BUCETA, Rosario Concepción RIESCO FAGUNDO
  • Patent number: 9993554
    Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 12, 2018
    Assignee: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO)
    Inventors: Manuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina
  • Patent number: 9808466
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: November 7, 2017
    Inventors: Joaquín Pastor Fernández, Rosa María Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martín Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Patent number: 9682991
    Abstract: There is provided compounds of formula (I), wherein R1, R2, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).
    Type: Grant
    Filed: December 31, 2010
    Date of Patent: June 20, 2017
    Assignee: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
    Inventors: Joaquín Pastor Fernández, Francisco Javier Ramos Lima, Ana Isabel Hernandez Higueras, Sonia Martínez González, Jose Ignacio Martín Hernando, Carl-Gustave Pierre Saluste, Esther Gonzalez Cantalapiedra, Carmen Blanco Aparicio, Antonio Rodríguez Hergueta, Ana Maria Garcia Collazo, Antonio Salgado Serrano, Beatriz Noya Marino
  • Publication number: 20160296528
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Application
    Filed: January 26, 2016
    Publication date: October 13, 2016
    Inventors: Joaquin Pastor Fernández, Rosa María Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martín Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Patent number: 9453031
    Abstract: Provided are chemical entities selected from compounds of formula (I), wherein R1, R2 and m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 27, 2016
    Assignee: Fundación Centro Nacional de Investigaciones Oncológicas Carlos III
    Inventors: Joaquín Pastor Fernández, Oscar Fernández-Capetillo Ruiz, Sonia Martínez González, Carmen Blanco Aparicio, María del Rosario Rico Ferreira, Luis Ignacio Toledo Lázaro, Sonsoles Rodríguez Arísteguí, Matilde Murga Costa, Carmen Varela Busto, Andrés Joaquín Lopez Contreras, Oliver Renner, María Nieto Soler, David Alvaro Cebrián Muñoz
  • Patent number: 9284334
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 15, 2016
    Assignee: Fundación Centro Nacional de Investigaciones Oncologicas Carlos III
    Inventors: Joaquin Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodriguez Hergueta, Jose Ignacio Martín Hernando, Carmen Blanco Aparicío, David Álvaro Cebrián Muñoz
  • Publication number: 20160024112
    Abstract: Provided are chemical entities selected from compounds of formula (I), wherein R1, R2 and m have meanings given in the description, and pharmaceutically acceptable salts, solvates and stereoisomers thereof, which are inhibitors of ATR and are potentially useful in the treatment of cancer. Further provided are pharmaceutical compositions of the chemical entities, combination products containing the chemical entities, the use of the compositions as therapeutic agents, and methods of treatment using these compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventors: Joaquín Pastor Fernández, Oscar Fernández-Capetillo Ruiz, Sonia Martínez González, Carmen Blanco Aparicio, María del Rosario Rico Ferreira, Luis Ignacio Toledo Lázaro, Sonsoles Rodríguez Arísteguí, Matilde Murga Costa, Carmen Varela Busto, Andrés Joaquín Lopez Contreras, Oliver Renner, María Nieto Soler, David Alvaro Cebrián Muñoz
  • Patent number: 9174953
    Abstract: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: November 3, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gregor James MacDonald, Gary John Tresadern, Andrés Avelino Trabanco-Suárez, Joaquin Pastor-Fernández
  • Patent number: 9073927
    Abstract: There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: July 7, 2015
    Assignee: FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
    Inventors: Joaquin Pastor Fernández, Sonia Martinez Gonzalez, Rosa Maria Álvarez Escobar, Antonio Rodriguez Hergueta, Jose Ignacio Martin Hernando, Francisco Javier Ramos Lima
  • Patent number: 9040707
    Abstract: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 26, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gregor James MacDonald, Andrés Avelino Trabanco-Suárez, Susana Conde-Ceide, Gary John Tresadern, José Manuel Bartolomé-Nebreda, Joaquin Pastor-Fernández
  • Patent number: 8859543
    Abstract: The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: October 14, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Gregor James MacDonald, Joaquin Pastor-Fernández, Michiel Luc Maria Van Gool, María Luz Martín-Martín, Greta Constantia Peter Vanhoof
  • Publication number: 20140256717
    Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 11, 2014
    Applicant: Centro Nacional de Investigaciones Oncológicas (CNIO)
    Inventors: Joaquín Pastor Fernández, Rosa Maria Álvarez Escobar, Rosario Concepción Riesco Fagundo, Ana Belén García García, Antonio Rodríguez Hergueta, Jose Ignacio Martin Hernando, Carmen Blanco Aparicio, David Álvaro Cebrián Muñoz
  • Patent number: 8815918
    Abstract: There is provided compounds of formula (I): wherein R1, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K) is desired and/or required, and particularly in the treatment of cancer.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: August 26, 2014
    Assignee: Centro Nacional de Investigaciones Oncologicas (CNIO)
    Inventors: Joaquin Pastor Fernández, Guido Kurz, Sonia Martinez Gonzalez
  • Patent number: 8778935
    Abstract: There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: July 15, 2014
    Assignee: Centro Nacional de Investigaciones Oncologicas (CNIO)
    Inventors: Joaquin Pastor Fernández, Sonia Martínez Gonzalez, Julen Oyarzabal Santamarina
  • Publication number: 20140154232
    Abstract: The first aspect of the invention relates to a phosphoinositide 3-kinase inhibitor for use in the treatment or prevention of a disease or condition associated with the expression of peroxisome proliferator-activated receptor gamma coactivator 1-? (Pgd1?) and/or uncoupling protein 1 (Thermogenin/Ucp1) in brown adipocytes. The disease or condition may be positive energy imbalance-associated, for example, obesity, an obesity-associated disease or condition, steatosis and biological aging (performance aging). Another aspect of the invention provides the use of a phosphoinositide 3-kinase inhibitor for promoting weight loss in an individual.
    Type: Application
    Filed: June 1, 2011
    Publication date: June 5, 2014
    Applicant: Centro Nacional De Investigaciones Oncologicas (CNIO)
    Inventors: Manuel Serrano Marugan, Joaquin Pastor Fernández, Sonia Martínez González, Ana Ortega Molina, James R. Bischoff, Julen Oyarzabal Santamarina
  • Patent number: 8716282
    Abstract: The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: May 6, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Joaquin Pastor-Fernández, José Manuel Bartolomé-Nebreda, Gregor James Macdonald, Susana Conde-Ceide, Óscar Delgado-González, Greta Constantia Peter Vanhoof, Michiel Luc Maria Van Gool, María Luz Martín-Martín, Sergio-Alvar Alonso-de Diego, Kelly Ann Swinney, Carina Leys, Johan Erwin Edmond Weerts, Stijn Wuyts
  • Publication number: 20130131057
    Abstract: There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
    Type: Application
    Filed: May 13, 2011
    Publication date: May 23, 2013
    Applicant: CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO
    Inventors: Joaquin Pastor Fernández, Sonia Martínez Gonzalez, Antonlo Rodriguez Hergueta, Francisco Javier Ramos Lima, Rosa Maria Alvarez Escobar, Ana Isabel Higueras Hernandez